Agile Therapeutics, Inc. (AGRX) stock announced a partnership with Pandia Health after which the stock became bullish today. AGRX stock price saw a push of 2.11% to reach $0.96 a share at the time of this writing. The stock was declining in the previous trade and went low by 2.86% at closing. Agile Therapeutics, Inc is the women’s health care stock that develops and commercializes women’s prescription contraceptive products in the U.S.

AGRX stock Partners with Pandia Health:

The latest development of AGRX stock is the partnership with Pandia Health which is an online telehealth service. This partnership will be beneficial for Agile stock in two ways.

• The partnership will be the basis of the telehealth relationship for Agile stock.
• This will prove to be an additional access point to Twirla transdermal system in a fast-growing channel.

Pandia Health is an online telehealth service that provides birth control prescriptions services to women. It also provides the facility of online appointments to expert birth control doctors. AGRX stock and Pandia anticipate phasing in the availability of Twirla in the second half of the current year.

AGRX stock Q2 2021 Performance:

• The agile stock reported 5,027 total prescriptions in the second quarter of 2021, 171% higher than the preceding quarter. New prescriptions increased by 103% from the preceding quarter to reach 2,857 in Q2,2021.
• AGRX stock had 2,087 health care providers by the end of the recently reported quarter and dispensed 2,033 prescriptions as refills.
• Agile generated $1.2 million net product sales revenue in the second quarter of 2021.
• Cost of product revenue for the AGRX stock reached $1.1 million by the end of the second quarter of 2021.
• Agile stock suffered a net loss of $17.6 million, or $0.20 per share in Q2,2021. This compares to a net loss of $10.8 million, or $0.12 per share in the second quarter of last year.

Q2,2021 Expenses of AGRX stock:

The agile stock spent $16.7 million in total operating expenses in the second quarter of 2021. These were significantly higher than $10.0 million in Q2,2020 due to increased selling and marketing expenses.

• Research and development expenses of AGRX stock were $0.9 million.
• Selling and marketing expenses for the recently reported quarter were $11.7 million.
• Agile stock spent $4.1 million in its general and administrative expenses.

Wrap Up:

The partnership with Pandia Health is a good sign for the AGRX stock’s growth. The management is striving hard for the positive progress of the stock however it lost almost 67% in the last 12 months. It is better to do deep fundamental as well as technical analysis before adding this stock to the portfolio.